On January 10, INSYS Therapeutics stock closed at $4.49, which represents ~28% growth from its stock price of $3.50 at the close of market on December 31. On January 2, 2019, INSYS Therapeutics stock price grew ~24.29% to reach $4.35 from its prior day close of $3.50 on December 31, 2018.
On January 4, the company’s stock price grew ~4.42% to reach $4.25 from its prior day close of $4.07 on January 3, 2019. Its price on January 10 was a 34% increase from its 52-week low of $3.35 on December 28. The company hit its 52-week high of $11.65 on August 30, 2018.
About INSYS Therapeutics
INSYS Therapeutics focuses on the development and commercialization of novel drugs and novel drug delivery systems utilizing its proprietary spray technology and competence in developing cannabinoid pharmaceuticals.
Of the five analysts tracking INSYS Therapeutics in January 2019, two of them recommended a “strong buy,” while two analysts recommended a “buy” rating. One analyst recommended a “sell” rating for INSYS Therapeutics. On January 11, INSYS Therapeutics had a consensus 12-month target price of $8.4, which represents ~87.08% return on investment over the next 12 months.
In January 2019, of the five analysts tracking Zynerba Pharmaceuticals (ZYNE), 80% of them recommended some form of a “buy” rating and among the 13 analysts tracking GW Pharmaceuticals (GWPH), ~85% of them recommended some form of a “buy” rating.
On January 10, Zynerba Pharmaceuticals (ZYNE) and GW Pharmaceuticals (GWPH) had consensus 12-month target prices of $18.4 and $173.17, respectively, which represents ~341.25% and ~38.16% returns on investment over the next 12 months.